|
MechanismENPP1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 in Subjects With Locally Advanced (Unresectable) or Metastatic Solid Tumors
This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors.
100 Clinical Results associated with Txinno Bioscience Co., Ltd.
0 Patents (Medical) associated with Txinno Bioscience Co., Ltd.
100 Deals associated with Txinno Bioscience Co., Ltd.
100 Translational Medicine associated with Txinno Bioscience Co., Ltd.